Abstract 599TiP
Background
Hepatocyte growth factor receptor (HGF)/mesothelial-epithelial transition (MET) pathway activation is known as an oncogenic driver in NSCLC. MET overexpression has been reported to be associated with worse clinical outcomes of NSCLCs. In China, the current second-line standard of care for EGFR/ALK/ROS1/METex14m-wildtype NSCLC with MET overexpression is mono-chemotherapy or immune checkpoint inhibitor, but with limited efficacy. Preclinically, the synergistic effect of savolitinib and docetaxel was tested in both CDX and PDX models. A phase I study explored the safety and tolerability of savolitinb plus docetaxel in advanced solid tumors. This study (NCT05777278) aims to explore the efficacy and safety of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression.
Trial design
This is an ongoing, phase I/II, pilot, open-label, single arm, single center, interventional study. Eligible patients will be those diagnosed with MET overexpression, EGFR/ALK/ROS1/METex14m-wildtype NSCLC in advanced stages and not treated with MET inhibitors. MET overexpression is defined as IHC 3+ in ≥50% of tumor cells. Patients will receive docetaxel (60 mg/m2, ivgtt, q3w) and savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after signing informed consent. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, other discontinuation criterion is met, or study completion. The primary objectives include assessing the efficacy by Objective Response Rate (ORR) and the safety and tolerability profile of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression. The secondary objective is to assess the efficacy through Progression-Free Survival (PFS), Duration of Response (DoR), Disease Control Rate (DCR), Overall Survival (OS), 12 months OS rate using investigator assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The exploratory objective is to assess efficacy in the MET-high (in 90% tumor cells IHC 3+) population.
Clinical trial identification
NCT05777278, 03/17/2023.
Legal entity responsible for the study
The authors.
Funding
AstraZeneca, China and Hutchison Whampoa, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract